Commerce Announces Third Quarter 2025 Financial Results

Commerce Announces Third Quarter 2025 Financial Results Third Quarter Total Revenue of $86.0 Million, an Increase of 3% Versus Prior Year. Total ARR of $355.7 Million, an Increase of 2% Versus Prior Year. Enterprise ARR of $269.2 Million, an Increase of 5% Versus Prior Year GlobeNewswire November 06, 2025 AUSTIN, Texas, Nov. 06, 2025 (GLOBE […]

Vetty CEO Jason Putnam Wins 2025 Inspiring Leaders Award

Vetty CEO Jason Putnam Wins 2025 Inspiring Leaders Award Employee-Nominated Program Honors Those Committed to Building People-First Organizations GlobeNewswire November 06, 2025 AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Vetty, the one-stop shop hiring acceleration platform, shared today that CEO Jason Putnam has won the 2025 Inspiring Leaders Award from the Inspiring Workplaces Group

TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances

TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances First study to report promising activity for an active immunotherapy combined with TAS-102 (LONSURF(R)) in late-stage MSS mCRC; TREOS advances Phase II programme with Charite – Universitatsmedizin Berlin and Junshi Biosciences GlobeNewswire November

Lantheus Announces Leadership Transition Plan

Lantheus Announces Leadership Transition Plan GlobeNewswire November 06, 2025 Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company's Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH),

OROCO CLOSES FIRST TRANCHE OF PRIVATE PLACEMENT FINANCING

OROCO CLOSES FIRST TRANCHE OF PRIVATE PLACEMENT FINANCING NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR U.S. DISSEMINATION GlobeNewswire November 06, 2025 VANCOUVER, Canada, Nov. 06, 2025 (GLOBE NEWSWIRE) — Oroco Resource Corp. (TSX-V: OCO, OTCQB: ORRCF) is pleased to announce the closing of an initial tranche of its non-brokered private placement announced

Verano Announces Exclusive Partnership with Raw Garden, a Leading California Cannabis Operator, to Launch Raw Garden Branded Products in New Jersey

Verano Announces Exclusive Partnership with Raw Garden, a Leading California Cannabis Operator, to Launch Raw Garden Branded Products in New Jersey GlobeNewswire November 06, 2025 Raw Garden Live Resin Terpene Cartridges and All-in-One Vapes will be sold at Verano's Four New Jersey Zen Leaf dispensaries and third-party retailers beginning November 11th. CHICAGO, Nov. 06, 2025

Inventus Announces Bulk Sample Processing Underway and Provides Drill Program Update

Inventus Announces Bulk Sample Processing Underway and Provides Drill Program Update GlobeNewswire November 06, 2025 TORONTO, Nov. 06, 2025 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce that processing of the 007 North bulk sample from its wholly-owned Pardo Gold Project, located 65 km northeast of Sudbury,

Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause

Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause Cendifensine demonstrates 92% reduction in number of hot flashes GlobeNewswire November 06, 2025 BASEL, Switzerland and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) — Noema Pharma AG today announced positive topline results from a Phase 2a, open-label

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF GlobeNewswire November 06, 2025 CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases GlobeNewswire November 06, 2025 Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company,

Scroll to Top